Svitlana Tyekucheva, Ph.D.
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
---|
Leukemia, Lymphocytic, Chronic, B-Cell | 14 | 2024 | 1640 | 1.270 |
Why?
|
Prostatic Neoplasms | 22 | 2023 | 11118 | 0.850 |
Why?
|
Paraffin Embedding | 3 | 2020 | 302 | 0.530 |
Why?
|
Tissue Fixation | 2 | 2017 | 241 | 0.490 |
Why?
|
Gene Expression Profiling | 12 | 2023 | 9418 | 0.440 |
Why?
|
Vidarabine | 4 | 2024 | 336 | 0.440 |
Why?
|
Formaldehyde | 1 | 2015 | 358 | 0.440 |
Why?
|
Stromal Cells | 1 | 2017 | 1330 | 0.390 |
Why?
|
Repetitive Sequences, Nucleic Acid | 2 | 2011 | 783 | 0.350 |
Why?
|
Genes, Neoplasm | 1 | 2011 | 370 | 0.340 |
Why?
|
Gene Expression Regulation, Neoplastic | 8 | 2023 | 8545 | 0.330 |
Why?
|
Prostate | 4 | 2023 | 1770 | 0.290 |
Why?
|
Cyclophosphamide | 6 | 2024 | 2218 | 0.280 |
Why?
|
Epithelial Cells | 2 | 2020 | 3667 | 0.270 |
Why?
|
Purines | 4 | 2022 | 605 | 0.260 |
Why?
|
PTEN Phosphohydrolase | 2 | 2021 | 1115 | 0.240 |
Why?
|
Tissue Array Analysis | 3 | 2021 | 550 | 0.240 |
Why?
|
Databases, Genetic | 5 | 2016 | 1742 | 0.240 |
Why?
|
Lipogenesis | 2 | 2018 | 214 | 0.240 |
Why?
|
RNA, Messenger | 2 | 2017 | 12796 | 0.220 |
Why?
|
Transcription, Genetic | 1 | 2017 | 7595 | 0.220 |
Why?
|
Ovarian Neoplasms | 3 | 2015 | 4876 | 0.220 |
Why?
|
Recombination, Genetic | 1 | 2008 | 1525 | 0.220 |
Why?
|
Isoquinolines | 2 | 2021 | 352 | 0.210 |
Why?
|
Antineoplastic Combined Chemotherapy Protocols | 7 | 2023 | 11740 | 0.210 |
Why?
|
Sulfonamides | 2 | 2022 | 1975 | 0.200 |
Why?
|
Thymidine Kinase | 1 | 2022 | 286 | 0.190 |
Why?
|
Pyrimethamine | 1 | 2021 | 94 | 0.180 |
Why?
|
Adenine | 2 | 2024 | 987 | 0.180 |
Why?
|
Piperidines | 3 | 2024 | 1656 | 0.180 |
Why?
|
Clinical Trials, Phase III as Topic | 3 | 2024 | 857 | 0.170 |
Why?
|
Genomics | 3 | 2023 | 5820 | 0.170 |
Why?
|
Endometrial Hyperplasia | 1 | 2020 | 97 | 0.170 |
Why?
|
Alu Elements | 2 | 2011 | 115 | 0.170 |
Why?
|
Metabolomics | 2 | 2020 | 1657 | 0.160 |
Why?
|
T-Lymphocytes, Regulatory | 2 | 2023 | 3077 | 0.160 |
Why?
|
Oligonucleotide Array Sequence Analysis | 2 | 2017 | 3779 | 0.150 |
Why?
|
Neoplasm Proteins | 2 | 2021 | 3612 | 0.150 |
Why?
|
Software | 1 | 2011 | 4434 | 0.140 |
Why?
|
Mutation | 7 | 2024 | 30045 | 0.140 |
Why?
|
Glioblastoma | 2 | 2011 | 3482 | 0.140 |
Why?
|
Squalene Monooxygenase | 1 | 2016 | 11 | 0.140 |
Why?
|
STAT3 Transcription Factor | 1 | 2021 | 871 | 0.140 |
Why?
|
Macaca | 2 | 2008 | 412 | 0.130 |
Why?
|
Pan troglodytes | 2 | 2007 | 225 | 0.130 |
Why?
|
Th17 Cells | 1 | 2023 | 794 | 0.130 |
Why?
|
Benzamides | 1 | 2021 | 1370 | 0.130 |
Why?
|
Pyrazines | 1 | 2021 | 1201 | 0.130 |
Why?
|
Evolution, Molecular | 4 | 2007 | 1887 | 0.120 |
Why?
|
Phosphatidylinositol 3-Kinases | 2 | 2022 | 2863 | 0.120 |
Why?
|
Humans | 56 | 2024 | 761423 | 0.120 |
Why?
|
Sequence Alignment | 3 | 2007 | 2179 | 0.120 |
Why?
|
Genes, Tumor Suppressor | 1 | 2019 | 1062 | 0.120 |
Why?
|
MAP Kinase Signaling System | 1 | 2021 | 1486 | 0.110 |
Why?
|
Enzyme Activators | 1 | 2014 | 57 | 0.110 |
Why?
|
Genome, Human | 5 | 2021 | 4425 | 0.110 |
Why?
|
AMP-Activated Protein Kinases | 2 | 2014 | 598 | 0.110 |
Why?
|
Autoimmunity | 1 | 2021 | 1355 | 0.110 |
Why?
|
Precancerous Conditions | 1 | 2020 | 980 | 0.110 |
Why?
|
Male | 32 | 2024 | 360736 | 0.110 |
Why?
|
Base Composition | 3 | 2008 | 290 | 0.110 |
Why?
|
Biological Products | 1 | 2022 | 912 | 0.110 |
Why?
|
Computational Biology | 5 | 2016 | 3517 | 0.110 |
Why?
|
Epithelium | 1 | 2017 | 1603 | 0.100 |
Why?
|
Epigenomics | 1 | 2018 | 942 | 0.100 |
Why?
|
Drug Resistance, Neoplasm | 3 | 2023 | 5305 | 0.100 |
Why?
|
Prostatectomy | 2 | 2017 | 1824 | 0.100 |
Why?
|
Receptors, Androgen | 1 | 2018 | 1079 | 0.100 |
Why?
|
RNA, Neoplasm | 1 | 2015 | 750 | 0.100 |
Why?
|
Proto-Oncogene Proteins c-myc | 1 | 2017 | 988 | 0.100 |
Why?
|
Signal Transduction | 4 | 2020 | 23441 | 0.100 |
Why?
|
Lymphoma, Large B-Cell, Diffuse | 1 | 2022 | 1405 | 0.100 |
Why?
|
ROC Curve | 4 | 2016 | 3580 | 0.100 |
Why?
|
Genes, Synthetic | 1 | 2011 | 88 | 0.090 |
Why?
|
Pyrimidines | 2 | 2023 | 3027 | 0.090 |
Why?
|
Cell Line, Tumor | 8 | 2021 | 16979 | 0.090 |
Why?
|
Prognosis | 9 | 2024 | 29620 | 0.090 |
Why?
|
Endometrial Neoplasms | 1 | 2020 | 1365 | 0.090 |
Why?
|
Molecular Sequence Annotation | 1 | 2013 | 522 | 0.090 |
Why?
|
Neoplasm Metastasis | 2 | 2018 | 4912 | 0.090 |
Why?
|
Quinazolinones | 2 | 2022 | 221 | 0.090 |
Why?
|
Long Interspersed Nucleotide Elements | 1 | 2011 | 330 | 0.080 |
Why?
|
Chromosomes, Human | 1 | 2011 | 442 | 0.080 |
Why?
|
Mass Spectrometry | 1 | 2017 | 2192 | 0.080 |
Why?
|
Aged | 16 | 2024 | 169235 | 0.080 |
Why?
|
Antineoplastic Agents | 2 | 2023 | 13637 | 0.080 |
Why?
|
Pyrazoles | 1 | 2019 | 2007 | 0.080 |
Why?
|
Age Factors | 2 | 2022 | 18400 | 0.080 |
Why?
|
Middle Aged | 17 | 2024 | 220826 | 0.080 |
Why?
|
Stress, Physiological | 1 | 2015 | 1403 | 0.080 |
Why?
|
Breast Neoplasms | 3 | 2022 | 21012 | 0.080 |
Why?
|
Chromatin | 2 | 2017 | 2960 | 0.070 |
Why?
|
Data Mining | 1 | 2013 | 551 | 0.070 |
Why?
|
NF-kappa B | 1 | 2016 | 2488 | 0.070 |
Why?
|
Area Under Curve | 1 | 2011 | 1638 | 0.070 |
Why?
|
Conserved Sequence | 2 | 2007 | 1165 | 0.070 |
Why?
|
Zebrafish Proteins | 1 | 2013 | 1014 | 0.070 |
Why?
|
Cholesterol | 1 | 2016 | 2902 | 0.070 |
Why?
|
Gene Dosage | 1 | 2011 | 1218 | 0.070 |
Why?
|
Protein Kinase Inhibitors | 2 | 2023 | 5665 | 0.070 |
Why?
|
Bone and Bones | 1 | 2017 | 2568 | 0.070 |
Why?
|
Cell Division | 1 | 2014 | 4466 | 0.070 |
Why?
|
Algorithms | 5 | 2020 | 14026 | 0.070 |
Why?
|
Models, Genetic | 3 | 2011 | 3446 | 0.070 |
Why?
|
Deoxyribonuclease I | 1 | 2006 | 224 | 0.060 |
Why?
|
Fatty Acids | 1 | 2014 | 1808 | 0.060 |
Why?
|
Microsatellite Repeats | 1 | 2007 | 785 | 0.060 |
Why?
|
Brain | 1 | 2011 | 27107 | 0.060 |
Why?
|
Quantitative Trait Loci | 1 | 2013 | 2116 | 0.060 |
Why?
|
Remission Induction | 2 | 2021 | 2395 | 0.060 |
Why?
|
Chromosomes, Human, X | 1 | 2006 | 321 | 0.060 |
Why?
|
Prospective Studies | 6 | 2022 | 54415 | 0.060 |
Why?
|
Hematopoiesis | 1 | 2013 | 2049 | 0.060 |
Why?
|
X Chromosome Inactivation | 1 | 2006 | 227 | 0.060 |
Why?
|
Exercise | 1 | 2021 | 5884 | 0.060 |
Why?
|
T-Lymphocytes | 1 | 2021 | 10194 | 0.060 |
Why?
|
Microsatellite Instability | 1 | 2007 | 716 | 0.060 |
Why?
|
Randomized Controlled Trials as Topic | 2 | 2024 | 10203 | 0.050 |
Why?
|
Chromosome Mapping | 2 | 2013 | 4638 | 0.050 |
Why?
|
DNA Transposable Elements | 1 | 2007 | 755 | 0.050 |
Why?
|
Female | 17 | 2024 | 392581 | 0.050 |
Why?
|
Chemokine CCL4 | 1 | 2023 | 126 | 0.050 |
Why?
|
Regulatory Sequences, Nucleic Acid | 1 | 2006 | 790 | 0.050 |
Why?
|
Follow-Up Studies | 5 | 2024 | 39117 | 0.050 |
Why?
|
Drug Administration Schedule | 2 | 2021 | 4852 | 0.050 |
Why?
|
Zebrafish | 1 | 2013 | 3007 | 0.050 |
Why?
|
Neoplasm Staging | 4 | 2020 | 11106 | 0.050 |
Why?
|
Ataxia Telangiectasia | 1 | 2022 | 107 | 0.050 |
Why?
|
Telomere | 1 | 2008 | 941 | 0.050 |
Why?
|
Cell Proliferation | 2 | 2016 | 10441 | 0.050 |
Why?
|
Biological Evolution | 1 | 2007 | 1072 | 0.050 |
Why?
|
Software Design | 2 | 2013 | 171 | 0.050 |
Why?
|
Adenocarcinoma | 1 | 2018 | 6339 | 0.050 |
Why?
|
Computer Simulation | 2 | 2011 | 6238 | 0.040 |
Why?
|
Stathmin | 1 | 2020 | 70 | 0.040 |
Why?
|
Etoposide | 1 | 2022 | 634 | 0.040 |
Why?
|
Disease Progression | 1 | 2017 | 13502 | 0.040 |
Why?
|
Kinetics | 1 | 2008 | 6374 | 0.040 |
Why?
|
Gene Knockdown Techniques | 2 | 2016 | 1612 | 0.040 |
Why?
|
Mutation, Missense | 1 | 2009 | 2571 | 0.040 |
Why?
|
Enhancer Elements, Genetic | 1 | 2006 | 1363 | 0.040 |
Why?
|
Gene Deletion | 1 | 2007 | 2667 | 0.040 |
Why?
|
Cell Transformation, Neoplastic | 1 | 2009 | 2824 | 0.040 |
Why?
|
Vincristine | 1 | 2022 | 1036 | 0.040 |
Why?
|
Sensitivity and Specificity | 2 | 2011 | 14664 | 0.040 |
Why?
|
DNA Mutational Analysis | 1 | 2007 | 4110 | 0.040 |
Why?
|
Extracellular Signal-Regulated MAP Kinases | 1 | 2021 | 615 | 0.040 |
Why?
|
Drug Repositioning | 1 | 2021 | 233 | 0.040 |
Why?
|
Regression Analysis | 1 | 2008 | 6343 | 0.040 |
Why?
|
Drug Screening Assays, Antitumor | 1 | 2021 | 718 | 0.040 |
Why?
|
Meta-Analysis as Topic | 1 | 2023 | 1377 | 0.040 |
Why?
|
Cyclin-Dependent Kinase 4 | 1 | 2022 | 561 | 0.040 |
Why?
|
Lymphocytes, Tumor-Infiltrating | 1 | 2024 | 1090 | 0.040 |
Why?
|
Endometrium | 1 | 2020 | 403 | 0.040 |
Why?
|
Genome | 1 | 2005 | 1740 | 0.040 |
Why?
|
Polymorphism, Single Nucleotide | 2 | 2014 | 15941 | 0.040 |
Why?
|
Gene Expression Regulation, Leukemic | 1 | 2021 | 651 | 0.040 |
Why?
|
Prednisone | 1 | 2022 | 1562 | 0.040 |
Why?
|
Methotrexate | 1 | 2024 | 1718 | 0.040 |
Why?
|
Proto-Oncogene Proteins c-bcl-2 | 1 | 2023 | 1405 | 0.030 |
Why?
|
Neutropenia | 1 | 2022 | 884 | 0.030 |
Why?
|
Aged, 80 and over | 4 | 2024 | 58956 | 0.030 |
Why?
|
Forkhead Transcription Factors | 1 | 2024 | 1613 | 0.030 |
Why?
|
Genes, myc | 1 | 2017 | 390 | 0.030 |
Why?
|
Immunoglobulin Heavy Chains | 1 | 2019 | 649 | 0.030 |
Why?
|
Tristetraprolin | 1 | 2016 | 38 | 0.030 |
Why?
|
Adult | 8 | 2024 | 221148 | 0.030 |
Why?
|
Adaptive Immunity | 1 | 2021 | 725 | 0.030 |
Why?
|
Neoplasm, Residual | 1 | 2021 | 1008 | 0.030 |
Why?
|
Gene Regulatory Networks | 2 | 2016 | 1743 | 0.030 |
Why?
|
Fluorescent Antibody Technique | 1 | 2020 | 2469 | 0.030 |
Why?
|
Genome-Wide Association Study | 2 | 2013 | 12688 | 0.030 |
Why?
|
Enzyme Activation | 1 | 2021 | 3597 | 0.030 |
Why?
|
Workflow | 1 | 2020 | 851 | 0.030 |
Why?
|
Hematologic Diseases | 1 | 2019 | 496 | 0.030 |
Why?
|
Doxorubicin | 1 | 2022 | 2224 | 0.030 |
Why?
|
Obesity | 1 | 2017 | 12938 | 0.030 |
Why?
|
Animals | 9 | 2018 | 168441 | 0.030 |
Why?
|
Cell Differentiation | 2 | 2023 | 11526 | 0.030 |
Why?
|
Treatment Outcome | 4 | 2024 | 64651 | 0.030 |
Why?
|
Oncogene Proteins, Fusion | 1 | 2022 | 1606 | 0.030 |
Why?
|
Neoplasms | 2 | 2016 | 22164 | 0.030 |
Why?
|
Sex Factors | 1 | 2008 | 10548 | 0.030 |
Why?
|
Acetyl-CoA Carboxylase | 1 | 2014 | 72 | 0.030 |
Why?
|
Immunoprecipitation | 1 | 2016 | 878 | 0.030 |
Why?
|
Disease-Free Survival | 1 | 2024 | 6814 | 0.030 |
Why?
|
G1 Phase | 1 | 2014 | 403 | 0.030 |
Why?
|
Proto-Oncogene Proteins c-akt | 1 | 2021 | 2455 | 0.030 |
Why?
|
Tumor Suppressor Proteins | 1 | 2022 | 2803 | 0.030 |
Why?
|
Flow Cytometry | 1 | 2023 | 5868 | 0.030 |
Why?
|
High-Throughput Nucleotide Sequencing | 1 | 2024 | 3639 | 0.030 |
Why?
|
Up-Regulation | 1 | 2021 | 4124 | 0.020 |
Why?
|
Reproducibility of Results | 2 | 2023 | 20093 | 0.020 |
Why?
|
Erythroid Cells | 1 | 2013 | 238 | 0.020 |
Why?
|
Receptor, erbB-2 | 1 | 2022 | 2557 | 0.020 |
Why?
|
Piperazines | 1 | 2022 | 2523 | 0.020 |
Why?
|
Administration, Oral | 1 | 2019 | 4016 | 0.020 |
Why?
|
Cell Cycle Proteins | 1 | 2022 | 3447 | 0.020 |
Why?
|
Neoadjuvant Therapy | 1 | 2022 | 2826 | 0.020 |
Why?
|
Chemokine CXCL12 | 1 | 2013 | 454 | 0.020 |
Why?
|
Genetic Predisposition to Disease | 1 | 2013 | 17912 | 0.020 |
Why?
|
Serotonin | 1 | 2015 | 1042 | 0.020 |
Why?
|
Lymphocyte Activation | 1 | 2021 | 5490 | 0.020 |
Why?
|
Xenograft Model Antitumor Assays | 1 | 2018 | 3602 | 0.020 |
Why?
|
Recurrence | 1 | 2023 | 8469 | 0.020 |
Why?
|
Protein Subunits | 1 | 2013 | 943 | 0.020 |
Why?
|
Bone Marrow | 1 | 2020 | 2910 | 0.020 |
Why?
|
Pyridines | 1 | 2022 | 2875 | 0.020 |
Why?
|
Molecular Sequence Data | 3 | 2007 | 17644 | 0.020 |
Why?
|
Tumor Microenvironment | 1 | 2023 | 3874 | 0.020 |
Why?
|
Metabolic Networks and Pathways | 1 | 2014 | 789 | 0.020 |
Why?
|
Chromatin Assembly and Disassembly | 1 | 2013 | 633 | 0.020 |
Why?
|
Single-Cell Analysis | 1 | 2020 | 2449 | 0.020 |
Why?
|
CD8-Positive T-Lymphocytes | 1 | 2023 | 4575 | 0.020 |
Why?
|
Immunity, Innate | 1 | 2021 | 3061 | 0.020 |
Why?
|
Tumor Suppressor Protein p53 | 1 | 2019 | 2916 | 0.020 |
Why?
|
Mitosis | 1 | 2014 | 1187 | 0.020 |
Why?
|
Dose-Response Relationship, Drug | 1 | 2021 | 10766 | 0.020 |
Why?
|
Boston | 1 | 2021 | 9330 | 0.020 |
Why?
|
Cohort Studies | 2 | 2022 | 41446 | 0.020 |
Why?
|
Mice | 4 | 2018 | 81509 | 0.020 |
Why?
|
Enzyme Inhibitors | 1 | 2018 | 3712 | 0.020 |
Why?
|
Bayes Theorem | 1 | 2016 | 2328 | 0.020 |
Why?
|
Codon, Initiator | 1 | 2007 | 51 | 0.020 |
Why?
|
Immunohistochemistry | 1 | 2021 | 11073 | 0.020 |
Why?
|
HeLa Cells | 1 | 2014 | 3093 | 0.020 |
Why?
|
B-Lymphocytes | 1 | 2021 | 4764 | 0.020 |
Why?
|
Codon, Terminator | 1 | 2007 | 125 | 0.020 |
Why?
|
Phosphoproteins | 1 | 2016 | 2448 | 0.020 |
Why?
|
Epigenesis, Genetic | 2 | 2013 | 3798 | 0.020 |
Why?
|
Cytokines | 1 | 2021 | 7392 | 0.020 |
Why?
|
Down-Regulation | 1 | 2014 | 2918 | 0.020 |
Why?
|
Base Pairing | 1 | 2006 | 140 | 0.020 |
Why?
|
Cats | 1 | 2007 | 975 | 0.020 |
Why?
|
Classification | 1 | 2006 | 127 | 0.020 |
Why?
|
Overweight | 1 | 2017 | 2413 | 0.020 |
Why?
|
Glucocorticoids | 1 | 2015 | 2161 | 0.020 |
Why?
|
Guinea Pigs | 1 | 2007 | 1317 | 0.020 |
Why?
|
Models, Statistical | 1 | 2020 | 5077 | 0.020 |
Why?
|
Adaptor Proteins, Signal Transducing | 1 | 2016 | 2898 | 0.020 |
Why?
|
Dosage Compensation, Genetic | 1 | 2006 | 207 | 0.020 |
Why?
|
Neovascularization, Pathologic | 1 | 2015 | 2644 | 0.020 |
Why?
|
Odds Ratio | 1 | 2017 | 9645 | 0.020 |
Why?
|
Mutagenesis, Insertional | 1 | 2007 | 656 | 0.020 |
Why?
|
Image Processing, Computer-Assisted | 1 | 2020 | 8999 | 0.010 |
Why?
|
Sequence Deletion | 1 | 2007 | 1494 | 0.010 |
Why?
|
Dogs | 1 | 2007 | 3839 | 0.010 |
Why?
|
Chromosomes | 1 | 2005 | 577 | 0.010 |
Why?
|
Logistic Models | 1 | 2017 | 13255 | 0.010 |
Why?
|
Genes | 1 | 2006 | 1844 | 0.010 |
Why?
|
Retrospective Studies | 2 | 2024 | 80582 | 0.010 |
Why?
|
Cattle | 1 | 2007 | 3848 | 0.010 |
Why?
|
Gene Expression | 1 | 2014 | 7584 | 0.010 |
Why?
|
Inflammation | 1 | 2021 | 10762 | 0.010 |
Why?
|
Rabbits | 1 | 2007 | 4779 | 0.010 |
Why?
|
Hematopoietic Stem Cells | 1 | 2013 | 3396 | 0.010 |
Why?
|
CpG Islands | 1 | 2005 | 1229 | 0.010 |
Why?
|
Survival Analysis | 1 | 2013 | 10089 | 0.010 |
Why?
|
Models, Biological | 1 | 2016 | 9469 | 0.010 |
Why?
|
Time Factors | 1 | 2021 | 39975 | 0.010 |
Why?
|
Body Mass Index | 1 | 2017 | 12951 | 0.010 |
Why?
|
Genetic Variation | 1 | 2014 | 6581 | 0.010 |
Why?
|
Base Sequence | 1 | 2007 | 12450 | 0.010 |
Why?
|
Linear Models | 1 | 2006 | 5869 | 0.010 |
Why?
|
Young Adult | 1 | 2022 | 59207 | 0.010 |
Why?
|
Mice, Inbred C57BL | 1 | 2014 | 22163 | 0.010 |
Why?
|
United States | 1 | 2021 | 72339 | 0.010 |
Why?
|
Rats | 1 | 2007 | 23742 | 0.010 |
Why?
|
Gene Expression Regulation | 1 | 2006 | 11902 | 0.000 |
Why?
|
Risk Factors | 1 | 2014 | 74167 | 0.000 |
Why?
|